Ann: Trading Halt, page-78

Thanks for providing the link.

In 2016 I commenced looking at VLA and while researching the term 'high unmet need' kept being used and I did some research on FDA site and not sure now if I saw these documents but that research made it clear to me the significance of this turn of phase and why it was constantly being used by the researchers.

It can make a huge difference to the timetable to approval particularly when the proposed treatment has a very low adverse event profile as you would obviously appreciate from your very detailed research.

In VLA's case up to this point in time not only does it have a very benign effect on trial participants but it appears to actually reduce the adverse event profile of the two FDA approved drugs when used in combination.